A Study to Assess the Safety and Tolerability, Including Gastrointestinal Safety, Pharmacokinetics and Pharmacodynamics of ASP7657 in Caucasian Healthy Male and Female Subjects
A Phase 1 Ascending Single and Multiple Oral Dose Study to Assess the Safety and Tolerability, Including Gastrointestinal Safety, Pharmacokinetics and Pharmacodynamics of ASP7657 in Caucasian Healthy Male and Female Subjects, Including a Food Effect Cohort
Sponsor: Astellas Pharma Europe B.V.
Terminated
Gastrointestinal safety findings
Other terminated trials from Astellas Pharma Europe B.V.
Other Healthy Subjects trials with similar outcome
A PHASE1 clinical study on Healthy Subjects and Pharmacodynamics of ASP7657, this trial is terminated or withdrawn. The trial is conducted by Astellas Pharma Europe B.V. and has accumulated 5 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE1
First recorded
Apr 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma Europe B.V.
For direct contact, visit the study record on ClinicalTrials.gov .